Novo Nordisk said it will slash the list prices of several of its popular pre-filled insulin pens and vials by up to 75%.
However, the company did not announce an expansion of its programs that cut patients’ out-of-pocket costs, which has been a focus of President Joe Biden and congressional Democrats. Novo Nordisk’s move comes two weeks after Eli Lilly announced a series of price cuts that would lower the price of the most commonly used forms of its insulin by 70%.
Novo Nordisk runs several programs to reduce the cost of insulin for diabetes patients, including a longstanding program that provides human insulin for about $25 a vial at Walmart. It is also available at CVS for $25. The company also offers co-pay savings cards that allow eligible patients in commercial insurance plans to pay as little as $25 to $35 for several insulin products. And in 2021, it created My$99Insulin, which provides a 30-day supply of a combination of insulin products for $99.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
WSJ News Exclusive | Novo Nordisk to Slash Insulin Prices by Up to 75%Breaking: Novo Nordisk, a large insulin maker, plans to cut the prices of its widely used products up to 75% to make them more affordable for patients. This follows a similar move by Eli Lilly.
Read more »
Novo Nordisk plans to cut insulin prices in U.S. by up to 75%Drugmaker Novo Nordisk said on Tuesday it would cut list prices for several insulin drugs by up to 75% in the United States, starting Jan. 1, 2024.
Read more »
Novo Nordisk Will Cut Insulin Cost in U.S. by Up to 75 PercentNovo Nordisk will slash the list price of several of its insulin drugs by as much as 75 percent, the company said Tuesday.
Read more »
Novo Nordisk plans to cut insulin prices up to 75%, following Eli LillyNovo will reduce the list price for NovoLog and NovoLog Mix 70/30 by 75%, and cut Novolin and Levemir’s list prices by 65% — but not until 2024.
Read more »
Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli LillyNovo Nordisk, along with Sanofi and Eli Lilly, make up most of the U.S. insulin market.
Read more »
Novo Nordisk Plans to Cut Insulin Prices in US by Up to 75%Drugmaker Novo Nordisk said on Tuesday it would cut list prices for several insulin drugs by up to 75% in the United States, starting January 1, 2024.
Read more »